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National Notifiable Infectious Diseases and Conditions: United States
TABLE 4. Reported cases of notifiable diseases and rates per 100,000, by age, excluding U.S. territories - - United States, 2016
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— — 2 0.01 8 0.02 17 0.04 68 0.10 112 0.11 38 0.08 2 247
Eastern equine
encephalitis virus disease
Neuroinvasive — — — — — — 1 0.00 1 0.00 2 0.00 3 0.01 — 7
Non-neuroinvasive — — — — — — — — — — — — — — — —
Jamestown Canyon virus
disease
Neuroinvasive — — — — — — — — 2 0.00 3 0.00 2 0.00 — 7
Non-neuroinvasive — — — — — — — — 1 0.00 3 0.00 4 0.01 — 8
La Crosse virus disease
Neuroinvasive — — 6 0.04 19 0.05 — — 3 0.00 1 0.00 2 0.00 — 31
Non-neuroinvasive — — 2 0.01 — — 1 0.00 1 0.00 — — — — — 4
Powassan virus disease
Neuroinvasive 1 0.03 — — — — — — — — 9 0.01 11 0.02 — 21
Non-neuroinvasive — — — — — — — — — — 1 0.00 — — — 1
St. Louis encephalitis
virus disease
Neuroinvasive — — — — — — — — — — 3 0.00 4 0.01 — 7
Non-neuroinvasive — — — — — — — — — — 1 0.00 — — — 1
West Nile virus disease
Neuroinvasive — — 4 0.03 19 0.05 45 0.10 145 0.22 581 0.56 514 1.04 — 1,308
Non-neuroinvasive — — 2 0.01 16 0.04 47 0.11 155 0.24 453 0.44 168 0.34 — 841
Western equine
encephalitis virus disease
Neuroinvasive — — — — — — — — — — — — — — — —
Non-neuroinvasive — — — — — — — — — — — — — — — —
Babesiosis
Total — — 8 0.07 37 0.13 41 0.13 158 0.34 794 1.07 865 2.54 7 1,910
Confirmed — — 5 0.04 27 0.09 28 0.09 126 0.27 620 0.84 772 2.27 7 1,585
Probable — — 3 0.03 10 0.03 13 0.04 32 0.07 174 0.24 93 0.27 — 325
Botulism
Total 140 3.53 1 0.01 — — 3 0.01 23 0.04 21 0.02 9 0.02 4 201
Foodborne — — 1 0.01 — — 3 0.01 13 0.02 8 0.01 6 0.01 — 31
Infant 140 3.53 — — — — — — — — — — — — 4 144
Other (wound &
unspecified)
— — — — — — — — 10 0.02 13 0.01 3 0.01 — 26
Brucellosis — — 2 0.01 10 0.02 3 0.01 29 0.04 59 0.06 23 0.05 1 127
Campylobacteriosis 1,762 44.38 5,703 35.74 4,897 11.93 6,809 15.65 10,835 16.55 19,081 18.36 10,922 22.18 111 60,120
Chancroid — — — — — — 2 0.00 4 0.01 1 0.00 — — — 7
Chlamydia trachomatis
infection
482 12.14 114 0.71 10,759 26.21 1,008,403 2,317.58 497,907 760.73 74,185 71.37 1,772 3.60 4,732 1,598,354
Cholera — — — — — — 2 0.00 3 0.00 7 0.01 3 0.01 — 15
Coccidioidomycosis * 7 0.43 53 0.81 491 2.91 1,097 6.15 2,320 8.69 4,948 11.81 2,898 14.69 15 11,829
Cryptosporidiosis
Total 200 5.04 1,842 11.54 2,212 5.39 1,862 4.28 3,254 4.97 2,797 2.69 1,225 2.49 61 13,453
Confirmed 131 3.30 1,259 7.89 1,503 3.66 1,205 2.77 2,054 3.14 1,790 1.72 664 1.35 31 8,637
Probable 69 1.74 583 3.65 709 1.73 657 1.51 1,200 1.83 1,007 0.97 561 1.14 30 4,816
Cyclosporiasis — — 5 0.03 10 0.03 38 0.10 124 0.21 277 0.29 77 0.17 6 537
Dengue virus infections †
Dengue 1 0.03 6 0.04 39 0.10 134 0.31 275 0.42 362 0.35 86 0.17 — 903
Dengue-like illness — — 1 0.01 1 0.00 7 0.02 14 0.02 10 0.01 3 0.01 4 40
Severe dengue — — — — 1 0.00 1 0.00 1 0.00 6 0.01 1 0.00 — 10






1 0.03 18 0.12 107 0.27 147 0.35 361 0.57 1,914 1.91 1,596 3.35 7 4,151
Ehrlichia chaffeensis
infection
1 0.03 6 0.04 46 0.12 87 0.21 153 0.24 610 0.61 466 0.98 8 1,377
Ehrlichia ewingii infection — — — — — — — — 2 0.00 9 0.01 11 0.02 — 22
Undetermined
ehrlichiosis/anaplasmosis
— — 3 0.02 15 0.04 15 0.04 36 0.06 76 0.08 54 0.11 1 200
Giardiasis 104 3.40 1,607 13.06 1,911 6.04 1,880 5.54 3,461 6.76 5,297 6.46 1,991 5.03 59 16,310
Gonorrhea 95 2.39 92 0.58 2,534 6.17 218,302 501.72 192,987 294.86 51,384 49.43 1,599 3.25 1,521 468,514
Haemophilus influenzae,
invasive disease
All ages, all serotypes 351 8.84 221 1.38 128 0.31 120 0.28 315 0.48 1,209 1.16 2,546 5.17 5 4,895
Age <5 years
Serotype b 19 0.48 11 0.07 — — — — — — — — — — — 30
Non-b serotype 78 1.96 81 0.51 — — — — — — — — — — — 159
Nontypeable 137 3.45 59 0.37 — — — — — — — — — — — 196
Unknown serotype 117 2.95 70 0.44 — — — — — — — — — — — 187




— — — — 1 0.00 1 0.00 2 0.00 2 0.00 — — — 6
Hantavirus pulmonary
syndrome
— — — — 2 0.00 4 0.01 7 0.01 12 0.01 6 0.01 — 31
Hemolytic uremic
syndrome post-diarrheal
9 0.23 143 0.92 100 0.25 13 0.03 10 0.02 11 0.01 19 0.04 2 307
Hepatitis §
A, acute 1 0.03 18 0.11 59 0.14 265 0.61 618 0.94 738 0.71 301 0.61 7 2,007
B, acute 1 0.03 — — 4 0.01 107 0.25 1,192 1.84 1,705 1.65 198 0.40 11 3,218
B, perinatal infection 17 0.43 15 0.38 — — — — — — — — — — — 32
C, acute 7 0.19 3 0.02 — — 531 1.30 1,528 2.47 784 0.80 68 0.15 21 2,942
Human immunodeficiency
virus diagnoses
39 0.98 15 0.09 67 0.16 7,243 16.65 15,630 23.88 11,052 10.63 729 1.48 — 34,775
Influenza-associated
pediatric mortality
8 0.20 26 0.16 39 0.10 9 0.07 — — — — — — — 82
Invasive pneumococcal
disease
All ages 395 13.42 717 6.05 464 1.52 315 0.97 1,425 2.96 7,305 9.40 6,972 18.68 33 17,626
Confirmed 393 13.35 715 6.04 464 1.52 315 0.97 1,425 2.96 7,299 9.39 6,959 18.64 33 17,603
Probable 2 0.07 2 0.02 — — — — — — 6 0.01 13 0.03 — 23
Age <5 years 408 12.86 734 5.75 — — — — — — — — — — — 1,142
Confirmed 406 12.80 731 5.72 — — — — — — — — — — — 1,137
Probable 2 0.06 3 0.02 — — — — — — — — — — — 5
Legionellosis 3 0.08 2 0.01 4 0.01 61 0.14 398 0.61 2,927 2.82 2,742 5.57 4 6,141
Leptospirosis — — — — 3 0.01 11 0.03 17 0.03 36 0.05 11 0.03 — 78
Listeriosis 34 0.86 1 0.01 5 0.01 20 0.05 61 0.09 183 0.18 480 0.97 2 786
Lyme disease
Total 21 0.53 1,283 8.08 5,776 14.13 3,495 8.07 4,822 7.40 12,970 12.53 7,360 15.02 702 36,429
Confirmed 20 0.51 1,074 6.76 4,472 10.94 2,343 5.41 3,311 5.08 9,355 9.04 5,045 10.30 583 26,203
Probable 1 0.03 209 1.32 1,304 3.19 1,152 2.66 1,511 2.32 3,615 3.49 2,315 4.72 119 10,226
Malaria 8 0.20 91 0.57 194 0.47 258 0.59 568 0.87 702 0.68 132 0.27 2 1,955
Measles
Total 5 0.13 9 0.06 14 0.03 16 0.04 26 0.04 15 0.01 — — — 85
Indigenous 4 0.10 7 0.04 8 0.02 15 0.03 21 0.03 13 0.01 — — — 68
Imported 1 0.03 2 0.01 6 0.01 1 0.00 5 0.01 2 0.00 — — — 17
Meningococcal disease
All serogroups 35 0.88 33 0.21 21 0.05 80 0.18 64 0.10 80 0.08 62 0.13 — 375
Serogroups ACWY 5 0.13 16 0.10 6 0.01 14 0.03 16 0.02 39 0.04 30 0.06 — 126
Serogroup B 18 0.45 10 0.06 6 0.01 25 0.06 11 0.02 8 0.01 8 0.02 — 86
Other serogroups 1 0.03 2 0.01 1 0.00 6 0.01 5 0.01 4 0.00 2 0.00 — 21
Unknown serogroup 11 0.28 5 0.03 8 0.02 35 0.08 32 0.05 29 0.03 22 0.04 — 142
Mumps 16 0.40 192 1.20 1,623 3.95 2,716 6.24 1,125 1.72 626 0.60 62 0.13 9 6,369
Novel Influenza A virus
infections
1 0.03 6 0.04 9 0.02 2 0.00 — — 4 0.00 — — 1 23
Pertussis 2,020 50.88 2,435 15.26 5,833 14.21 3,998 9.19 1,094 1.67 1,905 1.83 657 1.33 30 17,972
Plague — — — — — — 2 0.00 — — — — 2 0.00 — 4
Poliomyelitis, paralytic — — — — — — — — — — — — — — — —
Poliovirus infection,
nonparalytic
— — — — — — — — — — — — — — — —
Psittacosis — — — — — — 2 0.01 3 0.01 5 0.01 2 0.00 — 12
Q fever
Total — — 1 0.01 2 0.00 6 0.01 25 0.04 89 0.09 41 0.08 — 164
Acute — — 1 0.01 2 0.00 5 0.01 21 0.03 72 0.07 31 0.06 — 132
Chronic — — — — — — 1 0.00 4 0.01 17 0.02 10 0.02 — 32
Rabies
Human — — — — — — — — — — — — — — — —
Rubella — — — — — — — — 1 0.00 — — — — — 1
Rubella, congenital
syndrome
2 0.05 — — — — — — — — — — — — — 2




— — — — — — — — — — — — — — — —
Shiga toxin-producing
Escherichia coli ¶
340 8.56 1,782 11.17 1,400 3.41 1,320 3.03 1,275 1.95 1,159 1.12 806 1.64 87 8,169
Shigellosis 289 7.28 5,181 32.47 6,035 14.70 1,642 3.77 3,722 5.69 3,144 3.02 984 2.00 100 21,097
Smallpox — — — — — — — — — — — — — — — —
Spotted fever rickettsiosis
Total 2 0.05 45 0.28 186 0.46 353 0.82 823 1.27 1,924 1.86 931 1.90 5 4,269
Confirmed — — 2 0.01 14 0.03 13 0.03 23 0.04 67 0.06 35 0.07 — 154
Probable 2 0.05 43 0.27 172 0.42 340 0.79 800 1.23 1,857 1.80 896 1.83 5 4,115
Streptococcal toxic shock
syndrome
1 0.04 4 0.04 18 0.07 9 0.03 43 0.10 123 0.18 85 0.26 — 283
Syphilis
Total, all stages ** 634 15.97 4 0.03 42 0.10 17,544 40.32 41,556 63.49 26,306 25.31 1,867 3.79 89 88,042
Congenital 628 15.82 — — — — — — — — — — — — — 628
Primary and secondary — — 2 0.01 17 0.04 6,470 14.87 13,498 20.62 7,511 7.23 279 0.57 37 27,814
Tetanus — — — — 5 0.01 2 0.00 9 0.01 6 0.01 3 0.01 9 34
Toxic shock syndrome
(other than Streptococcal)
— — — — 15 0.05 17 0.06 3 0.01 5 0.01 — — — 40
Trichinellosis — — — — 2 0.01 2 0.00 4 0.01 14 0.01 4 0.01 — 26
Tuberculosis 48 1.21 176 1.10 163 0.40 938 2.16 2,206 3.37 3,470 3.34 2,264 4.60 7 9,272
Tularemia 1 0.03 14 0.09 19 0.05 17 0.04 29 0.04 99 0.10 51 0.10 — 230
Typhoid fever 2 0.05 32 0.20 79 0.19 78 0.18 111 0.17 60 0.06 7 0.01 7 376
Vancomycin-intermediate
Staphylococcus aureus
1 0.03 1 0.01 2 0.01 4 0.01 15 0.03 48 0.06 37 0.10 — 108
Vancomycin-resistant
Staphylococcus aureus
— — — — — — — — — — — — — — — —
Varicella morbidity 768 23.90 1,927 14.95 3,228 9.75 912 2.60 822 1.55 577 0.69 112 0.29 607 8,953
Varicella mortality U U U U U U U U U U U U U U U U
Vibriosis
Total 3 0.08 25 0.16 121 0.30 93 0.22 194 0.30 495 0.48 335 0.69 7 1,273
Confirmed 2 0.05 23 0.15 120 0.30 93 0.22 184 0.29 491 0.48 325 0.67 3 1,241




— — — — — — — — — — — — — — — —
Ebola virus — — — — — — — — — — — — — — — —
Guanarito virus — — — — — — — — — — — — — — — —
Junin virus — — — — — — — — — — — — — — — —
Lassa virus — — — — — — — — — — — — — — — —
Lujo virus — — — — — — — — — — — — — — — —
Machupo virus — — — — — — — — — — — — — — — —
Marburg virus — — — — — — — — — — — — — — — —
Sabia virus — — — — — — — — — — — — — — — —




25 0.63 — — — — — — — — — — — — 5 30
Zika virus disease, non-
congenital
3 0.08 22 0.14 180 0.44 764 1.76 1,810 2.77 2,077 2.00 272 0.55 4 5,132
Zika virus infection,
congenital ††
29 0.73 — — — — — — — — — — — — 16 45
Zika virus infection, non-
congenital
1 0.03 — — 6 0.01 295 0.68 545 0.83 51 0.05 12 0.02 1 911
—: No reported cases U: Unavailable
* Reportable in <25 states.
† Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of
anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).
§ Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's
Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm.
¶ Includes Escherichia coli O157:H7; shiga toxin-positive, serogroup non-O157; and shiga toxin positive, not serogrouped.
** Includes syphilis of all stages, including cases where stage of syphilis is not stated.
†† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional
data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at
https://www.cdc.gov/zika/reporting/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition
for congenital Zika virus disease or infection.
N o t e s :
These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported
by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC
weekly. Annual data may differ from previously reported weekly and quarterly data due to revision of information and delayed reporting.
The list of national notifiable infectious diseases and conditions for 2016 and their national surveillance case definitions are available at
https://wwwn.cdc.gov/nndss/conditions/notifiable/2016/infectious-diseases/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position
statements approved in 2015 by CSTE for national surveillance, that were implemented in January 2016, including updated surveillance case definitions for acute
hepatitis C and chronic hepatitis C virus infections. 2016 data are reported through June 30, 2017. Publication criteria for the finalized 2016 data are available at
/nndss/documents/2016_NNDSS_Publication_Criteria.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
Population estimates for incidence rates are July 1st, 2016 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the
resident population of the United States for July 1, 2011 - July 1, 2016, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African
American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2016), prepared
under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states as of June 26, 2017 are available at
https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2016 mid-year estimates from the U.S. Census
Bureau International Data Base accessed on July 24, 2017 at https://www.census.gov/population/international/data/idb/informationGateway.php. The choice of
population denominators for incidence is based on the availability of population data at the time of publication preparation.
NNDSS data displayed in the annual tables are accurate as of October 17, 2017; source data may be updated as additional information is received.
Annual tables for 2016 are available on CDC WONDER.
Annual summary reports from 1993-2015 are available as published in the MMWR.
Annual summary reports from 1952-1992 are available as published in the MMWR in the CDC Stacks.
National Notifiable Diseases Surveil lance System
Provided by CDC WONDER
